Small-Molecule FICD Inhibitors Suppress Endogenous and Pathologic FICD-Mediated Protein AMPylation
ACS Chemical Biology · 2025
DOI: 10.1021/acschembio.4c00847 ↗At a glance
Journal article in ACS Chemical Biology, 2025. Written by Bhaskar K Chatterjee and 8 co-authors. Institution: Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan 48109, United States. Major MEDLINE topics: Small Molecule Libraries, Enzyme Inhibitors, Adenosine Monophosphate. Cited 3 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.
Abstract (original language)
The AMP transferase, FICD, is an emerging drug target fine-tuning stress signaling in the endoplasmic reticulum (ER). FICD is a bifunctional enzyme, catalyzing both AMP addition (AMPylation) and removal (deAMPylation) from the ER-resident chaperone BiP/GRP78. Despite increasing evidence linking excessive BiP/GRP78 AMPylation to human diseases, small molecules that inhibit pathogenic FICD variants are lacking. Using an in vitro high-throughput screen, we identify two small-molecule FICD inhibitors, C22 and C73. Both molecules significantly inhibit FICD-mediated BiP/GRP78 AMPylation in intact cells while only weakly inhibiting BiP/GRP78 deAMPylation. C22 and C73 also inhibit pathogenic FICD variants and improve proinsulin processing in β cells. Our study identifies and validates FICD inhibitors, highlighting a novel therapeutic avenue against pathologic protein AMPylation.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Internal Medicine-Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Cellular and Molecular Biology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Vahlteich Medicinal Chemistry Core, University of Michigan, Ann Arbor, Michigan 48109, United States.
- College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
ORCID profiles: Charles L Brooks, Matthias C Truttmann
Funding
- NIH HHS
- NIDDK NIH HHS
- NIGMS NIH HHS
- University of Michigan
- Life Sciences Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of General Medical Sciences
Cite
APA
Chatterjee, B. K., Alam, M., Chakravorty, A., Lacy, S. M., Giblin, W., Rech, J., Brooks, C. L., Arvan, P., & Truttmann, M. C. (2025). Small-Molecule FICD Inhibitors Suppress Endogenous and Pathologic FICD-Mediated Protein AMPylation. ACS Chemical Biology. https://doi.org/10.1021/acschembio.4c00847
Vancouver
Chatterjee BK, Alam M, Chakravorty A, Lacy SM, Giblin W, Rech J, et al. Small-Molecule FICD Inhibitors Suppress Endogenous and Pathologic FICD-Mediated Protein AMPylation. ACS Chemical Biology. 2025. doi:10.1021/acschembio.4c00847
BibTeX
@article{Chatterjee2025,
author = {Chatterjee, Bhaskar K and Alam, Maroof and Chakravorty, Arghya and Lacy, Shannon M and Giblin, William and Rech, Jason and Brooks, Charles L and Arvan, Peter and Truttmann, Matthias C},
title = {Small-Molecule FICD Inhibitors Suppress Endogenous and Pathologic FICD-Mediated Protein AMPylation},
journal = {ACS Chemical Biology},
year = {2025},
doi = {10.1021/acschembio.4c00847}
}
EUVIMED